DOP065: Less anti-infliximab antibody formation in paediatric Crohn’s patients on concomitant immunomodulatorsECCO '16 Amsterdam
2016
DOP066: Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel diseaseECCO '16 Amsterdam
2016
DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a tertiary IBD centreECCO '16 Amsterdam
2016
DOP068: Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBDECCO '16 Amsterdam
2016
DOP069: Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustmentECCO '16 Amsterdam
2016
DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1ECCO '16 Amsterdam
2016
DOP072: Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomesECCO '16 Amsterdam
2016
DOP075: Looking beyond symptoms and disease activity to define disease severity in inflammatory bowel disease: results of an IOIBD specialist panelECCO '16 Amsterdam
2016
DOP076: A Danish cross-sectional study: autoimmune and chronic inflammatory disorders associated with ulcerative colitis.ECCO '16 Amsterdam
2016
DOP077: Immunochip analysis identifies multiple susceptibility loci for collagenous colitisECCO '16 Amsterdam
2016
DOP078: Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registryECCO '16 Amsterdam
2016
DOP079: Predictors of first neoplastic colonic lesion in patients with inflammatory bowel disease undergoing colonoscopic surveillanceECCO '16 Amsterdam
2016
DOP081: Outcomes of colitis-associated dysplasia after referral from the community to a tertiary centreECCO '16 Amsterdam
2016
DOP082: Proximity extension assay immunoassay technology identifies novel serum biomarkers that can diagnose and classify inflammatory bowel diseases: IBD Character ConsortiumECCO '16 Amsterdam
2016